Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Will the digital health bubble burst?

As a physician-turned investor, Dr. Sunny Kumar looks at the booming digital health market with the discernible eye of a clinician.

“The reality is private markets got a little bit exuberant in the last year for a variety of different reasons and we will likely see some degree of market correction,” Kumar says to Digital Health Business & Technology. “We are optimistic for the sector, as a whole, but are mindful of the fact that there may be some degree of correction, given the fact that not every single company can perform at the very, very top of expectations.”

Kumar and his fellow doctor-turned investor, Dr. Justin Norden, are partners at GSR Ventures, where they’ve led the investments for several digital health companies, including Medable, Alpha Medical and AppliedVR. Medable received a $304 million series D funding round in October, putting its total valuation at approximately $2.1 billion.

Source: Modern Healthcare

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!